GLP-1 coverage by insurance varies, and it is not widely available
In fact, participants in these trials experienced an average weight loss ranging from 12% to 15% of their body weight over the course of one year, surpassing the results achieved by any other currently available weight loss medication
When you puncture the stopper with a needle, the vacuum pulls whatever is in the syringe barrel into the vial with force
It is the race to control the global oral obesity drug market, oral GLP-1 adoption, triple agonist development, and the next generation of incretin therapies that could define a $150 billion metabolic health opportunity
Its not just that I was less hungryit felt like a switch had flipped in my brain, the same switch that drives addictive behaviors
Mounjaro is another brand-name drug that was FDA-approved for type 2 diabetes and contains the same active ingredient as Zepbound